Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Lilly

Zyprexa decline offset by other product growth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly 
 
4Q Revenues: $6.0 billion (-1%)

4Q Earnings: $827.2 million (-4%)

YTD Revenues: $22.6 billion (-7%) 

YTD Earnings: $4.1 billion (-6%)

Comments: Revenue in the U.S. was down 2% to $3.2 billion and revenue outside the U.S. was down 1% to $2.7 billion. Revenue decline included a 3% decrease due to lower volume, driven by the loss of patent exclusivity for Zyprexa in most major markets (-49% to $384.8 million), and 1% due to the unfavorable effect of foreign exchange rates. Humulin sales were down 1% in the quarter to $343.0 million, driven primarily by lower demand. Cymbalta sales were up 20% in the quarter to $1.4 billion. Alimta sales were up 7% to $684.3 million. Cialis sales were $513.4 million (+4%). Forteo sales were $314.6 million (+20%). Effient sales were up 33% to $120.6 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters